Feb 18, 2019 06:34 am
DUBLIN --
The "Acne
Vulgaris - Pipeline Insight, 2019" drug pipelines has been
added to ResearchAndMarkets.com's offering.
"Acne Vulgaris - Pipeline Insight, 2019" report offers comprehensive
Insight of the pipeline (under development) therapeutics scenario and
growth prospects across Acne Vulgaris development. The report provides
detailed coverage of the pipeline landscape for this mechanism of
action, equipped with data from multiple sources with complete pipeline
analysis by developmental stage, associated indications, route of
administration and molecule type.
Pipeline Products covered across the following Developmental
Stages:
-
Clinical
-
Non-clinical
-
Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for Acne
Vulgaris
Pipeline therapeutics development coverage provides descriptive product
profiles including (but not limited to) drug description, product
development and R&D activities encompassing clinical and pre-clinical
studies, designations, collaborations, licensing deals, grants,
technologies and patent details.
Pipeline Therapeutics assessment of products for Acne Vulgaris
The report assesses the active Acne Vulgaris pipeline products by
developmental stage, product type, molecule type, and administration
route.
Scope of the report
-
The report provides a snapshot of the pipeline development for the
Acne Vulgaris
-
The report covers pipeline activity across the complete product
development cycle i.e. clinical, pre-clinical and discovery stages for
the Acne Vulgaris
-
The report provides pipeline product profiles which includes product
description, developmental activities, licensors & collaborators and
chemical information
-
Provides pipeline assessment by monotherapy and combination therapy
products, stage of development, route of administration, and molecule
type for Acne Vulgaris
-
The report also covers the dormant and discontinued pipeline projects
related to the Acne Vulgaris
Reasons to Buy
-
Establish comprehensive understanding of the pipeline activity across
this Acne Vulgaris to formulate effective R&D strategies
-
Gather information of the emerging competitors having potentially
lucrative portfolio in this space and create effective counter
strategies to gain competitive advantage
-
Identify the relationship between the drugs and use it for target
finding, drug repurposing, and precision medicine
-
Plot corrective measures for pipeline projects by understanding the
pipeline depth and focus of Acne Vulgaris therapeutics
-
Devise in licensing and out licensing strategies by identifying
prospective partners with the most attractive projects to enhance and
expand business potential and scope
-
Modify the therapeutic portfolio by identifying inactive projects and
understanding the factors that might have halted their progress
Key Topics Covered:
1. Report Introduction
2. Acne Vulgaris Overview
3. Pipeline Therapeutics
-
An Overview of Pipeline Products for Acne Vulgaris
4. Comparative Analysis
5. Products in Clinical Stage
-
Product Description
-
Research and Development
-
Product Development Activities
6. Products in Pre-Clinical and Discovery Stage
-
Product Description
-
Research and Development
-
Product Development Activities
7. Therapeutic Assessment
-
Assessment by Route of Administration
-
Assessment by Stage and Route of Administration
-
Assessment by Molecule Type
-
Assessment by Stage and Molecule Type
8. Inactive Products
-
Product Description
-
Research and Development
-
Product Development Activities
Appendix
Companies Mentioned (Partial List)
-
Allergan Pharma
-
Almirall
-
AndroScience Corporation
-
AntibioTx
-
AntiCancer
-
AOBiome
-
Arkin Dermatology
-
Basilea Pharmaceutica
-
Biomar Microbial Technologies
-
BioPharmX
-
Blueberry Therapeutics
-
Botanix Pharmaceuticals Ltd.
-
Braintree Laboratories
-
Brickell Biotech Inc.
-
Cassiopea SpA
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/p932qc/acne_vulgaris?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190218005151/en/
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Acne
Drugs